Comparative Efficacy Studies: Tilmicosin vs Long-Acting Oxytetracycline or Ceftiofur for Treatment of Bovine Respiratory Disease in Newly Received Calves

Scott B. Laudert, PhD Carl A. Guthrie, DVM Elanco Animal Health Garden City, Kansas

Six comparative efficacy studies were conducted to evaluate tilmicosin (TIL) and either long-acting oxytetracycline (LAO) (3 studies) or ceftiofur (CFT) (3 studies) for treatment of bovine respiratory disease (BRD) in newly received salebarn or ranch calves. Two studies were conducted in each of the following locations: Colorado, Idaho and Oklahoma. Calves at each location were processed according to standard trial site procedures. Within each trial, morbid animals were identified and randomly assigned to the respective treatment groups (TIL vs LAO or TIL vs CFT). Morbid animals were identified as exhibiting clinical signs of BRD and a minimal rectal temperature of 104.0 F. All antibiotics were administered at label dosages. Following assignment to treatment, animals were housed in 10 to 20 head dedicated treatment pens for the remainder of the respective study. A total of 1109 calves were treated for BRD in the 6 studies (range, 121 to 200 BRD cases/site). Average initial body weight at the 6 locations was 513 lb (range, 412 to 627 lb). All cattle within a location were fed conventional starter and growing rations. Observations included rectal temperature and clinical impression score (CIS) on days 0 and 3, and body weight on days 0 and 28. Body weight was determined on day 100 in 3 studies. Treatment response (success or failure) was determined by evaluating each animal for improvement of the day 0 CIS, and rectal temperature at 72 hours post initial therapy. BRD therapy outcome was categorized as: treatment success (animal requiring only the initial experimental treatment therapy), treatment failure (animal requiring a second antibiotic regime within or at 72 hours post initial therapy), repull (animal requiring a second antibiotic regime at or after 96 hours post initial therapy), chronic (animal not responding to multiple antibiotic regimes) and mortality. All studies were conducted under a similar protocol. Three studies lasted 28 days and 3 studies lasted 100 days. Data within each study were analyzed using

analysis of variance techniques. Treatment success favored (P<.05) TIL in 2 of the 3 TIL vs LAO studies and in 2 of the 3 TIL vs CFT studies. Treatment success rates for the 3 TIL vs LAO studies were: 95 vs 72%, 43 vs 14% and 85 vs 75%, respectively, and for the 3 TIL vs CFT studies were: 73 vs 56%, 87 vs 79% and 93 vs 86%, respectively. Treatment failure favored (P<.05) TIL in 1 of the 3 TIL vs LAO studies and in 1 of the 3 TIL vs CFT studies. Treatment failure rates for the 3 TIL vs LAO studies were: 0 vs 3%, 50 vs 75% and 15 vs 25%, respectively, and for the 3 TIL vs CFT studies were: 24 vs 42%, 1 vs 4% and 5 vs 5%, respectively. Repull rate favored (P < .05) TIL in 1 of the 3 TIL vs LAO studies and in 1 of the 3 TIL vs CFT studies. Repull rates for the 3 TIL vs LAO studies were: 5 vs 25%, 6 vs 11% and 5 vs 4%, respectively, and for the 3 TIL vs CFT studies were: 5 vs 10%, 12 vs 18% and 2 vs 9%, respectively. The number of cattle classified as chronic was not different in any of the 6 studies. Mortality was not different in the TIL vs LAO studies and favored (P<.05) TIL in 1 of the 3 TIL vs CFT studies. Mortality rates for the 3 TIL vs LAO studies were: 0 vs 0%, 0 vs 1% and 0 vs 0%, respectively, and for the 3 TIL vs CFT studies were: 2 vs 10%, 1 vs 1% and 0 vs 0%, respectively. Feed performance is a reflection of therapeutic response in morbid cattle, (Bateman, K. G., et al, Can Vet J, 31:689-696, 1990). In our studies, day 28 average daily gain favored (P<.05) TIL in 2 of the 3 TIL vs LAO studies and in all 3 of the TIL vs CFT studies. Day 28 average daily gain (lb) for the 3 TIL vs LAO studies was: 2.69 vs 2.41, 1.71 vs 1.50 and 3.63 vs 3.79, respectively, and for the 3 TIL vs CFT studies was: 0.63 vs - 0.03, 0.64 vs 0.28and 2.68 vs 2.23, respectively. Day 100 average daily gain (lb) in 2 TIL vs LAO studies was: 3.10 vs 2.96 and 3.58 vs 3.59, respectively, and in 1 TIL vs CFT study was 3.02 vs 2.92, respectively. The combined results of these 6 studies confirm that tilmicosin is an effective antibiotic therapy for treating bovine respiratory disease.

Evaluation of Herd Serum Antibody Titers (A vital tool in formulating an effective herd vaccination program)

Bob Compton, DVM, Ph.D

Agricultural Consultant specializing in nutrition and immunology H.C. 33, Box 1175 Boise, ID 83706 - Phone: (208) 343-4321 Fax: (208) 331-2610.

The presence of antibodies in an animal at vaccination will impair the immune response elicited by a vaccine. Cattle that have not developed an acquired immune response (either by vaccination or natural infection) **are**